| pubmed-article:18163538 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18163538 | lifeskim:mentions | umls-concept:C0346647 | lld:lifeskim |
| pubmed-article:18163538 | lifeskim:mentions | umls-concept:C0162638 | lld:lifeskim |
| pubmed-article:18163538 | lifeskim:mentions | umls-concept:C0334227 | lld:lifeskim |
| pubmed-article:18163538 | lifeskim:mentions | umls-concept:C0596290 | lld:lifeskim |
| pubmed-article:18163538 | lifeskim:mentions | umls-concept:C0012863 | lld:lifeskim |
| pubmed-article:18163538 | lifeskim:mentions | umls-concept:C0441655 | lld:lifeskim |
| pubmed-article:18163538 | lifeskim:mentions | umls-concept:C0450442 | lld:lifeskim |
| pubmed-article:18163538 | lifeskim:mentions | umls-concept:C0205263 | lld:lifeskim |
| pubmed-article:18163538 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:18163538 | pubmed:dateCreated | 2008-1-17 | lld:pubmed |
| pubmed-article:18163538 | pubmed:abstractText | A series of substituted 9-aminoacridines is evaluated for antiproliferative activity toward pancreatic cancer cells. The results indicate that the compounds inhibit cell proliferation by inducing a G1-S phase arrest. A model is also developed that explains the molecular basis to inhibition through a DNA "threading" mechanism. We conclude that the drug-DNA complex formed blocks topoisomerase II binding and activity leading to catalytic inhibition of the enzyme and the induction of apoptosis and programmed cell death. | lld:pubmed |
| pubmed-article:18163538 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18163538 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18163538 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18163538 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18163538 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18163538 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18163538 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18163538 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18163538 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18163538 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18163538 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:18163538 | pubmed:issn | 0022-2623 | lld:pubmed |
| pubmed-article:18163538 | pubmed:author | pubmed-author:OugolkovAndre... | lld:pubmed |
| pubmed-article:18163538 | pubmed:author | pubmed-author:BilladeauDani... | lld:pubmed |
| pubmed-article:18163538 | pubmed:author | pubmed-author:FergusonDavid... | lld:pubmed |
| pubmed-article:18163538 | pubmed:author | pubmed-author:HiasaHiroshiH | lld:pubmed |
| pubmed-article:18163538 | pubmed:author | pubmed-author:GoodellJohn... | lld:pubmed |
| pubmed-article:18163538 | pubmed:author | pubmed-author:KaurHarneetH | lld:pubmed |
| pubmed-article:18163538 | pubmed:author | pubmed-author:RemmelRoryR | lld:pubmed |
| pubmed-article:18163538 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:18163538 | pubmed:day | 24 | lld:pubmed |
| pubmed-article:18163538 | pubmed:volume | 51 | lld:pubmed |
| pubmed-article:18163538 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18163538 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18163538 | pubmed:pagination | 179-82 | lld:pubmed |
| pubmed-article:18163538 | pubmed:dateRevised | 2010-12-3 | lld:pubmed |
| pubmed-article:18163538 | pubmed:meshHeading | pubmed-meshheading:18163538... | lld:pubmed |
| pubmed-article:18163538 | pubmed:meshHeading | pubmed-meshheading:18163538... | lld:pubmed |
| pubmed-article:18163538 | pubmed:meshHeading | pubmed-meshheading:18163538... | lld:pubmed |
| pubmed-article:18163538 | pubmed:meshHeading | pubmed-meshheading:18163538... | lld:pubmed |
| pubmed-article:18163538 | pubmed:meshHeading | pubmed-meshheading:18163538... | lld:pubmed |
| pubmed-article:18163538 | pubmed:meshHeading | pubmed-meshheading:18163538... | lld:pubmed |
| pubmed-article:18163538 | pubmed:meshHeading | pubmed-meshheading:18163538... | lld:pubmed |
| pubmed-article:18163538 | pubmed:meshHeading | pubmed-meshheading:18163538... | lld:pubmed |
| pubmed-article:18163538 | pubmed:meshHeading | pubmed-meshheading:18163538... | lld:pubmed |
| pubmed-article:18163538 | pubmed:meshHeading | pubmed-meshheading:18163538... | lld:pubmed |
| pubmed-article:18163538 | pubmed:meshHeading | pubmed-meshheading:18163538... | lld:pubmed |
| pubmed-article:18163538 | pubmed:meshHeading | pubmed-meshheading:18163538... | lld:pubmed |
| pubmed-article:18163538 | pubmed:meshHeading | pubmed-meshheading:18163538... | lld:pubmed |
| pubmed-article:18163538 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18163538 | pubmed:articleTitle | Acridine-based agents with topoisomerase II activity inhibit pancreatic cancer cell proliferation and induce apoptosis. | lld:pubmed |
| pubmed-article:18163538 | pubmed:affiliation | Department of Medicinal Chemistry, University of Minnesota, Minneapolis, Minnesota 55455, USA. | lld:pubmed |
| pubmed-article:18163538 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18163538 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:18163538 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:18163538 | lld:chembl |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18163538 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18163538 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18163538 | lld:pubmed |
